Maternal insulin and fat metabolism in pregnancies at risk for preeclampsia and gestational diabetes
Official title: Cardiometabolic Disease, Substrate Metabolism, and Abnormal Placental Pathology: a Multimodal Maternal-Fetal Study
Run by University of Tennessee Graduate School of Medicine · NCT07565727 · Data updated 2026-11-12
This project will try to see if insulin resistance and how the body burns fats early in pregnancy predict later preeclampsia or gestational diabetes in people at higher risk.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 45 Years |
| Sex | Women only |
| Enrollment | 50 (estimated) |
| Sponsor | University of Tennessee Graduate School of Medicine Academic / other |
| Locations | 1 site (Knoxville, Tennessee) |
| Status | Recruiting |
| Started | December 10, 2025 |
| Main results expected | August 2026 |
| Study ends | August 2027 |
| Registry record updated | May 4, 2026 |
| Trial ID | NCT07565727 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
People aged 18–45 with a pregnancy under 18 weeks who have at least one ACOG/USPSTF moderate or high risk factor for preeclampsia, who are willing to take aspirin and complete the required glucose testing and metabolic measurements, are ideal candidates.
✕Probably not a fit
People with preexisting type 1 or type 2 diabetes, current gestational diabetes, active bleeding or platelet disorders, thrombophilia, or those taking excluded medications are unlikely to benefit from this observational protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study enrolls pregnant people before 18 weeks' gestation who have at least one moderate or high risk factor for preeclampsia. Participants will undergo a 2-hour oral glucose tolerance test with blood draws to calculate HOMA-IR, plus measurements of lipid profiles, indirect calorimetry for substrate oxidation, and body composition; neonatal measures and surveys will also be collected. The aim is to link patterns of glucose and lipid metabolism, including maternal lipid oxidation, with later development of preeclampsia or gestational diabetes. No experimental treatments are given; standard-of-care aspirin prophylaxis is part of the protocol for eligible participants.
Why it matters
Potential benefit: If successful, this work could help identify metabolic signals early in pregnancy that predict later cardiometabolic complications, allowing earlier personalized prevention and monitoring.
How similar studies have gone: Previous research has linked maternal glucose and lipid levels to fetal growth and pregnancy outcomes, but few studies have specifically tied maternal lipid oxidation and HOMA-IR early in pregnancy to later preeclampsia or gestational diabetes, so this approach is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18-45 * Any pre-pregnancy BMI * At least one high risk OR one moderate risk factor for pre-eclampsia based on ACOG and USPSTF guidelines * Willingness to adhere to aspirin therapy * Willingness to undergo 2h OGTT for serum collection in addition to survey collection, indirect calorimetry, body composition measures, neonatal measures, etc. * Gestational age at enrollment \<18 weeks * Ability to speak, read, and communicate via English Exclusion Criteria: * Type 2 Diabetes Mellitus * Type 1 Diabetes Mellitus * Current gestational diabetes mellitus * Current/active platelet disorder or bleeding diathesis (thrombocytopenia of any etiology, idiopathic thrombocytopenic purpura/ITP, thrombotic thrombocytopenic purpura/TTP, von Willebrand disease, etc.) * Thrombophilia * Current use of NSAID for other indication (indomethacin, ibuprofen, etc.) * Current use of other immune-modulating agents and biologics (hydroxychloroquine, azathioprine, 6-mercaptopurine, IL-6 inhibitors, etc.) * Current or recent use of steroids * Current use of prophylactic or therapeutic anticoagulation * Medical contraindication to aspirin therapy * Molar pregnancy * Renal disease * Inability or unwillingness to give informed consent * Current psychiatric illness/social situation that would limit compliance with study requirements, as determined by the principal investigators
Where it's running
-
University of Tennessee Graduate School of Medicine
Knoxville, Tennessee, United States Recruiting
Study contacts
- Study coordinator: Jill M Maples, PhD
- Email: jmaples1@utmck.edu
- Phone: 865-305-9367
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Examining how aspirin metabolism relates to metabolic dysfunction in pregnant individuals at risk of preeclampsia
This study is trying to see how the way pregnant people process aspirin relates to their metabolic health and the health of their babies, especially for those at risk of preeclampsia.
-
Evaluating new ultrasound techniques for assessing placental health
This study is testing new ultrasound techniques to see if they can help tell the difference between healthy pregnancies and those with fetal growth issues.
-
Improving oral health during pregnancy to prevent complications
This study tests if treating gum disease in pregnant women can help their babies grow better and lower the chances of early delivery.
-
Prenatal Exercise to See How Cardio or Strength Training Affects Blood Sugar
This study tests whether different types and amounts of exercise during pregnancy can improve blood sugar control in women with gestational diabetes.
-
Two-Door Doulas: Enhanced vs Standard Medicaid Doula Care in Pregnancy
This trial tests whether an enhanced, earlier, and more frequent doula support program helps pregnant people on Medicaid feel less depression and anxiety after birth compared with the standard Medicaid doula care in Florida.
-
ASPIRE: Predicting Pregnancy Complications Using Blood and Eye Imaging
This study tests whether blood and eye imaging biomarkers can predict conditions like preeclampsia, fetal growth restriction, and gestational diabetes in first-time pregnant people carrying one baby.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.